Molecular Partners AG (MOLN) stock
MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.86+0.16 (+5.98%)
Close on Nov 17, 2026Market cap $115.47MP/E –Yield –
Molecular Partners price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Molecular Partners's price to sales ratio was 31.4× on Feb 27, 2026, against 26.0× a year earlier. Over the last 5 years it ranged from 0.6× to 79.4×, with a median of 21.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Feb 27, 2026 | 31.4× | +7.7 |
| 2025 | Dec 31, 2025 | 23.7× | +3.6 |
| 2024 | Dec 31, 2024 | 20.0× | +19.4 |
| 2023 | Dec 29, 2023 | 0.6× | −18.6 |
| 2022 | Dec 30, 2022 | 19.2× | −35.5 |
| 2021 | Dec 31, 2021 | 54.7× | – |
See a number that looks wrong?